![Blood Spotlight Sense and nonsense of high-dose cytarabine for acute myeloid leukemia | Semantic Scholar Blood Spotlight Sense and nonsense of high-dose cytarabine for acute myeloid leukemia | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/72808031e8479f21ef86e8beb190730a9bbc6273/2-Table1-1.png)
Blood Spotlight Sense and nonsense of high-dose cytarabine for acute myeloid leukemia | Semantic Scholar
Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells
![HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression - Journal of Biological Chemistry HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression - Journal of Biological Chemistry](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/7d627c2a-5aac-4ca1-ac51-9f78e9135464/gr1.jpg)
HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression - Journal of Biological Chemistry
![A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/32/2/643/F2.large.jpg)
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
![Frontiers | Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia Frontiers | Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia](https://www.frontiersin.org/files/Articles/507255/fonc-10-00296-HTML/image_m/fonc-10-00296-g001.jpg)
Frontiers | Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia
![A Randomized Investigation of High-Dose Versus Standard-Dose Cytosine Arabinoside With Daunorubicin in Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study - ScienceDirect A Randomized Investigation of High-Dose Versus Standard-Dose Cytosine Arabinoside With Daunorubicin in Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120615221-gr1.jpg)
A Randomized Investigation of High-Dose Versus Standard-Dose Cytosine Arabinoside With Daunorubicin in Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study - ScienceDirect
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia | Haematologica
![A: RFS and (B) OS of 130 patients given ARA-C at standard dose (SDAC,... | Download Scientific Diagram A: RFS and (B) OS of 130 patients given ARA-C at standard dose (SDAC,... | Download Scientific Diagram](https://www.researchgate.net/profile/Adriano-Venditti/publication/268686914/figure/fig3/AS:272602618920989@1442004937841/A-RFS-and-B-OS-of-130-patients-given-ARA-C-at-standard-dose-SDAC-78-red-line-or.png)
A: RFS and (B) OS of 130 patients given ARA-C at standard dose (SDAC,... | Download Scientific Diagram
Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells | PLOS ONE
![A DNA/HDAC dual‐targeting drug CY190602 with significantly enhanced anticancer potency | EMBO Molecular Medicine A DNA/HDAC dual‐targeting drug CY190602 with significantly enhanced anticancer potency | EMBO Molecular Medicine](https://www.embopress.org/cms/asset/419475db-b572-4cc5-bd68-c4a4743a460b/emmm201404580-fig-0003-m.jpg)
A DNA/HDAC dual‐targeting drug CY190602 with significantly enhanced anticancer potency | EMBO Molecular Medicine
![The HDI model of HDAC inhibition in leukemic cells . HDI inhibits HDAC,... | Download Scientific Diagram The HDI model of HDAC inhibition in leukemic cells . HDI inhibits HDAC,... | Download Scientific Diagram](https://www.researchgate.net/profile/Elahe-Khodadi/publication/283055946/figure/fig3/AS:287121090461698@1445466410499/The-HDI-model-of-HDAC-inhibition-in-leukemic-cells-HDI-inhibits-HDAC-which-leads-to_Q640.jpg)
The HDI model of HDAC inhibition in leukemic cells . HDI inhibits HDAC,... | Download Scientific Diagram
![Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy - ScienceDirect Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1521692612000837-gr1.jpg)
Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy - ScienceDirect
![HDAC deacethylation mechanism in leukemic cells . Overexpression of... | Download Scientific Diagram HDAC deacethylation mechanism in leukemic cells . Overexpression of... | Download Scientific Diagram](https://www.researchgate.net/profile/Elahe-Khodadi/publication/283055946/figure/fig1/AS:287121090461696@1445466410222/HDAC-deacethylation-mechanism-in-leukemic-cells-Overexpression-of-HDAC-and-decreased_Q640.jpg)
HDAC deacethylation mechanism in leukemic cells . Overexpression of... | Download Scientific Diagram
![Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine](https://www.embopress.org/cms/asset/0d9a6ccd-b391-44ac-94b2-74651438f447/emmm201910419-abs-0001-m.jpg)
Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine
![Marine Drugs | Free Full-Text | Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms | HTML Marine Drugs | Free Full-Text | Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms | HTML](https://www.mdpi.com/marinedrugs/marinedrugs-19-00488/article_deploy/html/images/marinedrugs-19-00488-g001.png)